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Abstract 32 
 33 
In the quantification of positron emission tomography (PET) radiotracer binding, a very commonly 34 
used method is the reference tissue model (RTM). RTM necessitates a proper reference region and 35 
cerebellum is the most commonly used for G-protein coupled receptors, however, the cerebellum is 36 
a heterogenous brain region and can be divided into subregions. We investigated regional 37 
differences in uptake within the grey matter of the cerebellar hemispheres (CH) and the cerebellar 38 
vermis (CV) for five PET radioligands targeting the serotonin system. Furthermore, we looked into 39 
the impact of choosing either CH, CV or CV+CH as a reference region when quantifying the 40 
binding of the five radioligands. 41 
The PET and MR images are all part of the Cimbi database: 5-HT1AR ([11C]CUMI,n=8), 5-HT1BR 42 
([11C]AZ10419369,n=36), 5-HT2AR ([11C]Cimbi-36,n=29), 5-HT4R ([11C]SB207145,n=59), and 5-43 
HTT ([11C]DASB,n=100). We employed the software packages SUIT and FreeSurfer to delineate 44 
CV and CH and quantified mean standardized uptake values (SUV) as well as non-displaceable 45 
neocortical binding potential (BPND). Statistical difference was assessed within subjects and with 46 
paired nonparametric two-sided Wilcoxon signed rank tests.  47 
We demonstrated radioligand specific regional differences in cerebellar uptake between CV and CH 48 
for four out of the five radioligands. These differences may be ascribed to differences in 49 
concentration of the receptor or transporter in question in CV vs. CH, could reflect off-target 50 
binding of the radioligands or differences in the non-displaceable binding in the two regions. Our 51 
data highlight the importance of validating each radioligand carefully for defining the optimal 52 
reference region.  53 
 54 
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1 Introduction 63 
 64 
Positron emission tomography (PET) allows for the visualization of the density of neurotransmitter 65 
receptors and transporters and is one of the key tools for in vivo imaging. PET is used to quantify 66 
neuroreceptor density in the human brain using binding potential as a metric. Binding potential is 67 
defined as the concentration of a radioligand specifically bound to a target receptor divided by a 68 
reference concentration. In general, three different reference concentrations can be used: (1) free 69 
(non-protein bound) radioligand concentration in plasma, (2) total (free plus protein-bound) 70 
radioligand concentration in plasma and (3) non-displaceable radioligand (i.e. the non-specifically 71 
bound radioligand plus the free ligand in tissue). Each of these references represents a balance 72 
between interpretability and convenience.  73 
 74 
The first two methods require measuring the radioligand concentration in plasma which necessitates 75 
arterial blood measurements (venous blood sampling is possible in some cases). However, the 76 
invasiveness of a required arterial line hampers its feasibility in a clinical setting. Furthermore, the 77 
measurements of the parent (non-metabolized) radioligand in plasma can be challenging and labor-78 
intensive. The non-displaceable method, on the other hand, does not require blood sampling at all, 79 
but merely requires a region that is free of target of interest. This region then represents the non-80 
displaceable concentration and can be determined using the measured PET image. There have been 81 
several methods developed to compute the binding potential using a reference region; collectively, 82 
these are known as reference tissue models (RTM)1. The binding potential computed relative to the 83 
non-displaceable concentration is referred to as BPND. 84 
 85 
A RTM, however, necessitates a proper reference region. RTMs have three basic assumptions: the 86 
reference region is devoid of the target of interest; the non-displaceable binding, VND, is the same 87 
for both the target region and the reference region; and the blood volume contribution is negligible 88 
in both the reference and target regions. The quantification will be biased if these assumptions are 89 
violated, and the bias may not be a simple scaling factor2. For G-protein coupled receptors, such as 90 
those in the serotonin and dopamine systems, the cerebellum is often used as reference region as it 91 
is assumed to be receptor free. However, studies of serotonin receptors suggest that some 92 
subregions of the cerebellum may not be receptor free; properly identifying these subregions may 93 
be important when using cerebellum as a reference region3,4. 94 
Cerebellum as a reference region for 5-HT receptors 
 4 
 
The cerebellum can be subdivided into subregions that may vary in terms of their suitability as 95 
reference tissue. A subregion of specific interest in serotonin imaging is the cerebellar vermis (CV). 96 
It can be defined in different ways, but is mostly used to indicate the “midline” of the cerebellum5. 97 
Previous studies have reported increased 5-HT1ARs in CV compared to the cerebellar hemispheres 98 
(CH) in both healthy volunteers3 and in schizophrenic patients6. But the results are controversial, 99 
since another group could not confirm the earlier post-mortem findings of increased 5-HT1AR 100 
binding in CV in patients with schizophrenia in vivo7.  101 
In order to shed more light on the use of cerebellum as a reference region and specifically the 102 
properties of CV, we utilized the Center for Integrated Molecular Brain Imaging (Cimbi) database 8 103 
to investigate regional differences in binding within the grey matter of CH and CV for five different 104 
PET radioligands targeting the serotonin system. 105 
 106 
2 Materials and Methods 107 
 108 
2.1 Participants 109 
 110 
The Cimbi database8 established normative data for the 5-HT1A 9, 5-HT1B10, 5-HT2A11and the 5-111 
HT412 receptors as well as the 5-HTT13. We selected data of healthy controls for five radioligands 112 
targeting these receptors and transporter. All subjects were scanned on a Siemens high resolution 113 
research tomography (HRRT) PET scanner. Corresponding T1-weighted structural magnetic 114 
resonance (MR) scans were acquired on four different Siemens MR scanners with standard 115 
parameters. Demographic details about the participants can be seen in Table 1 of the supplementary 116 
material. All procedures followed were in accordance with the ethical standards of the responsible 117 
committees on human experimentation (institutional and national) and with the Declaration of 118 
Helsinki 1975, as revised in 2008. Informed consent was obtained from all patients for being 119 
included in the study.  120 
 121 
2.2 Positron Emission Tomography and Structural Magnetic Resonance Imaging 122 
  123 
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The PET and MR images used in our analysis are all part of the Cimbi database. In detail the 124 
following PET scans were available for analysis: 5-HT1AR ([11C]CUMI, n=8), 5-HT1BR 125 
([11C]AZ10419369, n=36), 5-HT2AR ([11C]Cimbi-36, n=29), 5-HT4R ([11C]SB207145, n=59), and 126 
5-HTT ([11C]DASB, n=100).  127 
 128 
PET list-mode data were acquired with a Siemens HRRT scanner operating in 3D-acquisition mode, 129 
with an approximate in-plane resolution of 2 mm. PET frames were reconstructed using a 3D-130 
OSEM-PSF algorithm 14–16. Scan time and frame length was tracer dependent, see 8 for details. 131 
Realignment of dynamic PET frames was performed using AIR 5.2.517 to account for within-scan 132 
motion. A rigid realignment transform was evaluated for individual frames believed to have 133 
sufficient count statistics. Frames were smoothed using a 10 mm Gaussian filter, and voxels less 134 
than 80% of the maximum intensity were discarded. The remaining voxels were used to evaluate 135 
the rigid transformation to the reference frame using least-squares intensity rescaling as the cost-136 
function. The original frames were finally realigned by applying the rigid transformation. Frames 137 
with lower count statistics were aligned accordingly to the first or last realigned frame. Details of 138 
the realignment procedure can be found in Table 2 of the supplementary material.  139 
 140 
Structural MRIs were acquired on four different Siemens scanners - two Siemens Verio, a Siemens 141 
Prisma and a Siemens Trio. The detailed acquisition parameters can be found in the supplementary 142 
material. The structural MRI data were analyzed with FreeSurfer (v5.3)18 to define tissue types and 143 
regions, including cortical grey matter. The individual cortical surfaces were reconstructed using the 144 
structural MRI corrected for gradient non-linearity. PET-MR co-registration was estimated using 145 
boundary-based registration19 between the time-weighted sum of the PET time activity curves 146 
(TACs) and the structural MRI20. FreeSurfer was used to define a segmentation of the cerebellum in 147 
grey and white matter (see Figure 1). Additionally, we employed the software package SUIT 2.721 148 
to segment the cerebellum into sub regions – namely CH and CV (also see Figure 1). The CH was 149 
defined as those voxels in the cerebellum that were not labelled as CV. Finally, grey matter 150 
cerebellar labels were further refined by limiting them to the intersection of the FreeSurfer labels 151 
with the cerebellum labelled by SUIT. This removes peripheral overlabeling sometimes present in 152 
the FreeSurfer as well as the SUIT segmentation.  153 
 154 
[insert Figure 1.] 155 
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2.3 Analysis 156 
 157 
We computed the volume of CV, CH and the white matter in the cerebellar hemispheres by 158 
counting the number of voxels in each segmented region and dividing by the size of the voxels in 159 
the segmentation. For each subject we quantified a measure of radioligand uptake in CV, CH and 160 
CH+CV. The mean standard uptake values (SUV) weighted by the frame length was used as a 161 
measure of brain uptake, where SUV is defined as the TAC in the region-of-interest divided by 162 
injected dose per kg bodyweight (g/ml)22.  163 
 164 
Additionally, we calculated the neocortical BPND with the simplified reference tissue model 165 
(SRTM)23, where we used CV, CH or CH+CV as reference region, respectively. Regional TACs 166 
were used for the quantification. We are aware of the fact that we are violating the assumptions for 167 
SRTM if CV has specific binding and additionally is a small region, but since SRTM is commonly 168 
used to quantify non-displaceable binding potential, we want to assess the bias that including CV 169 
yields when using SRTM.  170 
 171 
Statistical difference was assessed within subjects and with paired nonparametric two-sided 172 
Wilcoxon signed rank tests using Matlab (Mathworks Inc., MA, vers. R2013a). 173 
 174 
3 Results 175 
 176 
In our segmentations the cerebellum as a whole had on average a volume of 147±15 cm3 in our 177 
population of 232 young healthy adults (for age ranges see Table 1 of the supplementary material).  178 
 Looking at the subregions, CV had an average volume of 6±0.7 cm3, CH had an average volume of 179 
110±12 cm3 and the white matter of the cerebellar hemispheres was 31±4 cm3. Hence, CV 180 
comprises about 4% of the cerebellum, CH covers 75%, and the white matter covers 21% of the 181 
whole cerebellum in our dataset.  182 
 183 
Regarding differences in cerebellar uptake and neocortical binding potential based on different 184 
reference region definitions, we give an overview of the results in Table 3 of the supplementary 185 
material.  186 
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Figure 2 shows the percentage difference between CV and CH in mean SUV defined as 187 
(meanSUVCV-meanSUVCH)/ meanSUVCH. A significant difference between CH and CV was found 188 
for [11C]CUMI, [11C]AZ10419369, [11C]Cimbi-36 and [11C]DASB (Table 1 (a)). We found no 189 
significant difference in uptake between CH and CV for [11C]SB207145. The difference in uptake 190 
between CV and CH ranges from 7- 20% for [11C]CUMI, 0-17% for [11C]AZ10419369, 0-8% for 191 
[11C]Cimbi-36 and 0-16% for [11C]DASB.  192 
And even though CV is much smaller than CH and covers only about 4% of the whole cerebellum, 193 
this statistical difference persists when we compare CH vs. CH+CV (Table 1 (a)).  194 
 195 
[insert Figure 2.]  196 
 197 
Next, we calculated neocortical BPND using different reference regions, where we used CH, CV or 198 
CH+CV as reference. The mean and standard deviation as well as the range of neocortical BPND are 199 
given in Table 4 of the supplementary material. Figure 3 shows the percentage difference in 200 
neocortical BPND defined as (BPND,CV - BPND,CH)/ BPND,CH. A significant difference in BPND was 201 
found for [11C]CUMI-101, [11C]AZ10419369 and [11C]DASB (Table 1 (b)). We found no 202 
significant difference in BPND for [11C]Cimbi-36  and [11C]SB207145. When only using the CV as 203 
reference region, the effect size on the neocortical BPND is large: The difference in BPND between 204 
CV and CH ranges from 11-32% for [11C]CUMI, from 0-40% for [11C]AZ10419369, from 0-15% 205 
for [11C]Cimbi-36  and from 0-50% for [11C]DASB.  206 
 207 
[insert Figure 3.] 208 
 209 
Figure 4 shows the percentage difference (BPND,CV+CH - BPND,CH)/ BPND,CH, i.e. when CV and CH is 210 
combined to a single reference region (CV+CH). As for the mean SUV we also found the same 211 
statistical differences when we compare the neocortical BPND based on CH vs. CH+CV (Table 1 212 
(b)). The differences are though much smaller and range from 0-2% for [11C]CUMI-101, from 0-2% 213 
for [11C]AZ10419369, from 0-1% for [11C]Cimbi-36  and from 0-3% for [11C]DASB. 214 
 215 
[insert Figure 4.] 216 
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4 Discussion 217 
 218 
Our measurement of global cerebellar size fits well with other MR based studies, e.g. 24 which 219 
reported a total cerebellar volume of 141±13 cm3 in a population of 97 young (age 33.7 ± 13.6 220 
years) healthy adults.  221 
 222 
Regarding the differences in uptake measured by mean SUV the results from the literature vary 223 
from receptor to receptor. Looking at the 5-HT1AR there has been in vitro evidence of limited 5-224 
HT1AR binding in CV36. In vivo experiments have reported an individual with exceptionally high 225 
accumulation of [11C]WAY-100635 in the cerebellum, which was most marked in cerebellar 226 
cortical grey matter and vermis 25, as well as significantly reduced cerebellar grey matter (~ 30%) 227 
binding after a challenge with pindolol, a 5-HT1AR antagonist 26. This aligns with our findings 228 
where [11C]CUMI-101 had higher uptake in the CV than CH. 229 
 230 
For the 5-HT1B receptor sparse evidence exists. In vitro results using [3H]GR125743 report that 231 
binding in general was low in the cerebellum27, but higher in an inner layer of cerebellar cortex 232 
close to the white matter28. To our knowledge there have been no in vivo reports of higher binding 233 
in CH versus CV. In 29 the authors report a low concentration of [11C]AZ10419369 binding in 234 
cerebellar cortex and state that BPND values obtained with kinetic compartment analysis and RTM 235 
using the cerebellar cortex as reference region were well correlated.  Furthermore, a blocking study 236 
in humans using [11C]AZ10419369 and AZD378330 states that there is no evident reduction in 237 
radioactivity in the cerebellum meaning some subjects showed reduced binding in the cerebellum 238 
after blocking whereas others did not. Our results using [11C]AZ10419369 indicate the same as the 239 
autoradiography data and point to a slightly higher uptake in CH compared to CV. 240 
 241 
The literature for the 5-HT2AR is more cohesive on the subject of cerebellar binding. Several in 242 
vitro studies report low to very low 5-HT2AR densities over the different layers of cerebellar cortex 243 
using [3H]MDL10090727 and ketanserin31; they concluded that the cerebellum is virtually devoid of 244 
5-HT2ARs (with [3H]MDL100907)32. Furthermore, there is also an in vivo study that reports no 245 
detectable cerebellar binding to 5-HT2ARs using [18F]Altanserin33. Our SUV results contradict the 246 
literature and indicate a higher uptake in CV compared to CH using [11C]Cimbi-36; however, there 247 
was no significant difference in BPND when using CH or CV as reference. The reason that the SUV 248 
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but not the BPND is significantly different between CV and CH might stem from the sensitivity of 249 
the SUV which is a more direct and model-free measure. A higher uptake in CV could be explained 250 
by the fact that Cimbi-36 is less selective for the 5-HT2AR compared to MDL100907: The ratio of 251 
5-HT2AR/5-HT2CR selectivity for [11C]Cimbi-36 is 15 34 while it is 142 for MDL10090735. Thus, 252 
the binding of Cimbi-36 in CV could be due to the off-target binding to the 5-HT2CR. On the other 253 
hand the presence of 5-HT2CR in the cerebellum is unconfirmed36.  254 
 255 
Three in vitro studies of 5-HT4R report low and inconsistently detectable levels in cerebellar cortex 256 
with [3H]GR11380837 or find no evidence for specific binding in the cerebellum with 257 
[125I]SB20771027 38. The autoradiography findings are in line with our results, where we see no 258 
difference in cerebellar subregion uptake for [11C]SB207145. 259 
 260 
Finally, there exists conflicting evidence for the binding of 5-HTT receptors in cerebellum.  One in 261 
vitro study reported that concentration of the 5-HTT protein in both cerebellar cortex and white 262 
matter is very low39. However, Varnäs at al. reported  that [3H]Citalopram binding was concentrated 263 
in a band that probably corresponded to the Purkinje cell layer27.  Parsey et al. found specific 5-264 
HTT binding to be much higher in CV (8.4 fmol/mg) compared with CH (1.25 fmol/mg), and 265 
cerebellar white matter (0.23 fmol/mg) using [3H]cyanoimipramine40. Conversely, one in vivo 266 
studies states the opposite and reports a negligible level of specific binding with [11C]McN 565241. 267 
Our results seem to support the findings in 40 in that we see higher uptake of [11C]DASB in CV 268 
compared to CH.  269 
 270 
We also evaluated the influence of using different cerebellar sub regions as reference region for 271 
neocortical RTM. The differences in neocortical binding when using CH or CH+CV are in general 272 
small. The largest differences were found when using CV as reference. Since CV is a very small 273 
region, the signal is very noisy and hence the RTM is affected by this higher noise level. 274 
Furthermore, the protein/lipid composition may differ between CV and CH and hence the kinetics 275 
of CV as reference region could be unsuitable. The influence of including or excluding CV from the 276 
reference region when calculating cortical BPND is small, yielding a difference in cortical BPND 277 
below 5% for all tracers.  278 
 279 
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Because we find significant differences in uptake and neocortical BPND for several 5-HT receptors, 280 
we hypothesize that there is 1) a difference in the actual receptor densities in the two areas, 2) that 281 
there exists off-target binding of the radioligand or 3) that there is a difference in the non-282 
displaceable binding in the two tissue types. Fortunately, we can also show that the differences 283 
between including or excluding CV when calculating neocortical BPND are small. They can, 284 
however, bias results and since the bias is different for each patient and each tracer2 this can be a 285 
confounding factor especially for small size PET studies.  286 
 287 
Furthermore, the bias from including or excluding CV is possibly larger in disease groups, because 288 
the distribution and quantity of receptors can be different in disease groups compared to controls 289 
and hence influences group studies to a greater degree. For example, a recent article covering 290 
contradictory results regarding 5-HT1A receptors in major depressive disorder 42 highlighted the 291 
importance of choosing the right reference region for determining the BPND. Hence, the authors also 292 
recommended using common methodological methods for quantification of BPND in order to make 293 
studies comparable across multiple centres. This includes a common and robust way to define a 294 
reference region from MR. 295 
 296 
Based on our results we recommend to use CH as reference region and exclude CV. But for the 5-297 
HT1B receptor where we have found a slightly higher uptake of [11C]AZ10419369 in CH compared 298 
to CV, we recommend to use CH as reference region with caution. We cannot recommend to only 299 
use CV as reference region, since our BPND calculations vary strongly due to the small size and 300 
possibly different tissue composition of the region.  301 
 302 
Limitations of our study are that we cannot address age effects, since our population consists of 303 
young healthy individuals. Our findings cannot be generalized to clinical populations, because 304 
differences in the receptor distribution within the cerebellum has been found in patient populations 305 
such as schizophrenics and major depression disorder6,43.  306 
 307 
4.1 Conclusion 308 
 309 
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We demonstrated radioligand specific regional differences in cerebellar uptake, of relevance for its 310 
use as a reference region in PET imaging. These differences may be ascribed to differences in 311 
concentration of the receptor or transporter in question in CV vs. CH, could reflect off-target 312 
binding of the radioligands or differences in the non-displaceable binding in the two tissue types. 313 
There was evidence from post-mortem autoradiography and in vivo studies of the presence of 5-314 
HT1ARs in CV and we observed a significantly higher [11C]CUMI-101 uptake in the CV compared 315 
to CH. We also found significantly higher uptake of [11C]AZ10419369 in CH compared to CV, 316 
which is consistent with an autoradiographic study showing presence of 5-HT1BRs in CH. Our 317 
results on 5-HT2A receptor binding in CV were contrary to the in vitro as well as in vivo literature, 318 
but this may be explained by the binding of [11C]Cimbi-36 to the 5-HT2CR. With regard to 5-HT4 319 
receptor binding in the cerebellum, our results agreed with the literature. Finally, we found a higher 320 
uptake of [11C]DASB in CV compared to CH; this agrees with 40 but has not been confirmed in 321 
other studies.  322 
Besides regional differences in cerebellar uptake we also evaluated the influence of using different 323 
cerebellar regions for neocortical RTM. While we observe large difference when using CV alone as 324 
reference region, which is most likely due to the unsuitability of SRTM for this region, the 325 
influence of including or excluding CV from the reference region is small and yields a difference in 326 
cortical BPND below 5% for all tracers.  327 
 328 
In conclusion, our data highlighted the importance of validating each radioligand carefully with 329 
regard to the suitability of including or excluding CV in the reference region definition. 330 
 331 
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Figure 1. 461 
The cerebellar hemispheres are segmented in CH (yellow) and cerebellar white matter (blue) by 462 
FreeSurfer, while CV is delineated along the midline with SUIT (red). The peripheral overlabeling 463 
by using outliers of the intersection of SUIT and FreeSurfer are shown in pink. 464 
 465 
 466 
 467 
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Figure 2. Percentage difference given as (meanSUVCV-meanSUVCH)/ meanSUVCH  between mean 468 
SUV in CV and CH. The box plot displays the median as central line, the edges of the box are the 469 
25th and 75th percentiles, the whiskers extend to the minimal and maximal data points, and all values 470 
are plotted as dots individually. Significance of within subjects, paired nonparametric two-sided 471 
Wilcoxon signed rank tests is given by *:p<0.05, **:p<0.01, ***:p<0.001, ****:p<0.0001. 472 
. 473 
 474 
 475 
 476 
 477 
 478 
 479 
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Figure 3. Percentage difference defined as (BPND,CV- BPND,CH)/ BPND,CH  in neocortical BPND 480 
calculated based on CV and CH. The box plot displays the median as central line, the edges of the 481 
box are the 25th and 75th percentiles, the whiskers extend to the minimal and maximal data points, 482 
and all values are plotted as dots individually. Significance of within subjects, paired nonparametric 483 
two-sided Wilcoxon signed rank tests is given by *:p<0.05, **:p<0.01, ***:p<0.001, ****:p<0.0001. 484 
 485 
 486 
 487 
Figure 4. Percentage difference given as (BPND,CV+CH- BPND,CH)/ BPND,CH  in neocortical BPND 488 
calculated based on CV+CH and CH. The box plot displays the median as central line, the edges of 489 
the box are the 25th and 75th percentiles, the whiskers extend to the minimal and maximal data points, 490 
and all values are plotted as dots individually. Significance of within subjects, paired nonparametric 491 
two-sided Wilcoxon signed rank tests is given by *:p<0.05, **:p<0.01, ***:p<0.001, ****:p<0.0001. 492 
 493 
